Evidence map›Paper›PMID 28560583›Full record

ArticleEJNMMI research2017

Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using

Neel Patel, Sarah Able, Danny Allen, Emmanouil Fokas, Bart Cornelissen, Fergus V Gleeson, Adrian L Harris, Katherine A Vallis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Neel PatelDepartment of Radiology, Churchill Hospital, Headington, OX3 7LE, Oxford, UK. neel.patel@gtc.ox.ac.uk.ORCID http://orcid.org/0000-0002-7412-5493
Sarah AbleCRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.
Danny AllenCRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.
Emmanouil FokasCRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.
Bart CornelissenCRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.
Fergus V GleesonDepartment of Radiology, Churchill Hospital, Headington, OX3 7LE, Oxford, UK.
Adrian L HarrisDepartment of Oncology, University of Oxford, Oxford, UK.
Katherine A VallisCRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.
University of Oxford · GBChurchill Hospital · GB

Funding

Cancer Research UK 11359Cancer Research UK 11564Cancer Research UK 16466Cancer Research UK 18974Cancer Research UK 22906Cancer Research UK 23970
6 · The paper itself

Abstract

backgroundThe ability to image vascular endothelial growth factor (VEGF) could enable prospective, non-invasive monitoring of patients receiving anti-angiogenic therapy. This study investigates the specificity and pharmacokinetics of

resultsSpecific uptake of

conclusions

Indexed as

AngiogenesisBevacizumabCancerRadionuclideRapamycin

Identifiers

PMID28560583
PMCPMC5449352
OpenAlexW2620380971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.